Vivos Therapeutics 관리

관리 기준 확인 4/4

Vivos Therapeutics CEO는 R. Huntsman, Sep2016 에 임명되었습니다 의 임기는 8.17 년입니다. 총 연간 보상은 $ 657.70K, 70.5% 로 구성됩니다. 70.5% 급여 및 29.5% 보너스(회사 주식 및 옵션 포함). 는 $ 215.53K 가치에 해당하는 회사 주식의 1.53% 직접 소유합니다. 215.53K. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 4.4 년입니다.

주요 정보

R. Huntsman

최고 경영자

US$657.7k

총 보상

CEO 급여 비율	70.5%
CEO 임기	8.2yrs
CEO 소유권	1.5%
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	4.4yrs

최근 관리 업데이트

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Nov 12

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Sep 10

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Apr 25

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Feb 02

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Apr 18

Vivos Therapeutics again delays Q2 2022 results

Aug 23

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Jun 29

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

May 21

Vivos Therapeutics: First Take After The Broad Market Sell-Off

Mar 06

CEO 보상 분석

R. Huntsman 의 보수는 Vivos Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$13m
Jun 30 2024	n/a	n/a	-US$12m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$658k	US$463k	-US$14m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$938k	US$385k	-US$24m
Sep 30 2022	n/a	n/a	-US$25m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$1m	US$344k	-US$20m
Sep 30 2021	n/a	n/a	-US$24m
Jun 30 2021	n/a	n/a	-US$21m
Mar 31 2021	n/a	n/a	-US$19m
Dec 31 2020	US$455k	US$252k	-US$18m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$11m
Mar 31 2020	n/a	n/a	-US$12m
Dec 31 2019	US$328k	US$249k	-US$12m
Dec 31 2018	US$284k	US$249k	-US$9m

보상 대 시장: R. 의 총 보상 ($USD 657.70K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 650.80K ).

보상과 수익: R. 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

R. Huntsman (66 yo)

8.2yrs

테뉴어

US$657,701

보상

Mr. R. Kirk Hunstman is the Co-Founder of Vivos Therapeutics, Inc. since September 2016 and has been its Chief Executive Officer and Director since September 2016 and has been its Chairman of the Board sin...

리더십 팀

이름	위치	테뉴어	보상	소유권
R. Huntsman	Co-Founder	8.2yrs	US$657.70k	1.53% $ 215.5k
Bradford Amman	CFO, Treasurer & Secretary	6.1yrs	US$400.04k	0.0017% $ 236.2
Todd Huntsman	Co-Founder & Senior VP of Product and Technology	less than a year	데이터 없음	데이터 없음
RaeAnn Byrnes	Co-Founder and Senior VP of Events & Clinical Advisory Services	no data	데이터 없음	데이터 없음
Susan McCullough	Co-Founder & Executive VP of Operations	less than a year	데이터 없음	데이터 없음
Nicholas DeGennaro	Senior Vice President of Medical Integration Division	5.1yrs	데이터 없음	데이터 없음
Ruth Hembree	Senior Vice President of Practice Services	no data	데이터 없음	데이터 없음
Stephanie Huebner	Senior Vice President of Dental Service Integration	2.8yrs	데이터 없음	데이터 없음
John Ballard	Senior Vice President of Technology	less than a year	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

경험이 풍부한 관리: VVOS 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
R. Huntsman	Co-Founder	8.2yrs	US$657.70k	1.53% $ 215.5k
Leonard Sokolow	Independent Director	4.4yrs	US$63.00k	0.0084% $ 1.2k
Anja Krammer	Independent Director	4.4yrs	US$58.00k	0% $ 0
Mark Lindsay	Independent Director	4.4yrs	US$58.00k	0% $ 0
Matthew Thompson	Independent Director	4.4yrs	US$63.00k	0% $ 0
Edward Zuckerberg	Member of Medical & Clinical Advisory Board	3.8yrs	데이터 없음	데이터 없음
Ralph Green	Independent Director	4.4yrs	US$58.00k	0% $ 0
Michael Gelb	Member of Medical & Clinical Advisory Board	3.8yrs	데이터 없음	데이터 없음
Manisha Witmans	Member of Medical & Clinical Advisory Board	3.8yrs	데이터 없음	데이터 없음
Tammarie Heit	Member of Medical & Clinical Advisory Board	3.8yrs	데이터 없음	데이터 없음
Clete Kushida	Co-Chair of Medical & Clinical Advisory Board	3.8yrs	데이터 없음	데이터 없음
Cecilia Wu	Co-Chair of Medical & Clinical Advisory Board	no data	데이터 없음	데이터 없음

4.4yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: VVOS 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.

Vivos Therapeutics 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Vivos Therapeutics, Inc., Annual General Meeting, Nov 26, 2024

High number of new and inexperienced directors

Vivos Therapeutics, Inc., Annual General Meeting, Sep 22, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Vivos Therapeutics, Inc., Annual General Meeting, Aug 25, 2022

Recent updates

Consensus EPS estimates upgraded to US$2.02 loss, revenue downgraded

Price target decreased by 14% to US$6.30

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Vivos Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Vivos Therapeutics, Inc., Annual General Meeting, Nov 26, 2024

New major risk - Share price stability

Vivos Therapeutics, Inc. Receives FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Consensus estimates of losses per share improve by 31%

New major risk - Financial position

Vivos Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Vivos Therapeutics Announces Positive Results from 7-Month Multi-Site Pilot of Its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics, Inc. announced that it has received $7.5 million in funding

Vivos Therapeutics Provides Non-Compliance Update

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Vivos Therapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Vivos Therapeutics, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Vivos Therapeutics, Inc. Receives FDA Clearance to Vivos Care Oral Appliances to Treat Severe OSA in Adults

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Vivos Therapeutics, Inc. Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Vivos Therapeutics, Inc. Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.7% to US$45.00

High number of new and inexperienced directors

Vivos Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Vivos Therapeutics, Inc. announced that it has received $4.000003 million in funding

Vivos Therapeutics, Inc. announced that it expects to receive $4.000003 million in funding

Vivos Therapeutics Provides Nasdaq Compliance Update

Vivos Therapeutics Receives a Written Notice from the Nasdaq

Vivos Therapeutics, Inc., Annual General Meeting, Sep 22, 2023

Vivos Therapeutics Receives Non-Compliance Letterer from Nasdaq

Vivos Therapeutics, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Vivos Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Vivos Therapeutics, Inc. to Report Q1, 2023 Results on Jun 08, 2023

Vivos Therapeutics Receives Staff Deficiency Notice from The Nasdaq Stock Market Due to Failure to File its Form 10-Q

Vivos Therapeutics, Inc. announced delayed 10-Q filing

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Consensus EPS estimates upgraded to US$0.40 loss

Price target decreased by 17% to US$1.88

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.26 loss per share (vs US$0.26 loss in 3Q 2021)

Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements

Vivos Therapeutics, Inc. Receives FDA 510(k) Clearance of its DNA Oral Appliance for Treatment of Obstructive Sleep Apnea

Vivos Therapeutics, Inc. to Report Q3, 2022 Results on Dec 20, 2022

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

Vivos Therapeutics Receives a Staff Deficiency Notice from The Nasdaq Stock Market

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Vivos Therapeutics again delays Q2 2022 results

Vivos Therapeutics, Inc. announced delayed 10-Q filing

Vivos Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Vivos Therapeutics, Inc. Receives Multiple Class I Clearances by Therapeutic Goods Administration (TGA) of Australia

Vivos Therapeutics, Inc., Annual General Meeting, Aug 25, 2022

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Vivos Therapeutics, Inc. Presents Positive Results from a Retrospective Study with Vivos Patients

Consensus revenue estimates fall by 25%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$9.00

High number of new and inexperienced directors

No longer forecast to breakeven